Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease

• Published in: Diabetes & vascular disease research Vol. 9; no. 3; p. 205
• Main Authors: Farnier, Michel, Retterstøl, Kjetil, Steinmetz, Armin, Császár, Albert
• Format: Journal Article
• Language: English
• Published: England 01-07-2012
• Subjects: Aged; Azetidines - therapeutic use; Cardiovascular Diseases - complications; Cholesterol, HDL - drug effects; Cholesterol, LDL - drug effects; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate - therapeutic use; Humans; Hyperlipidemias - complications; Hyperlipidemias - drug therapy; Hypolipidemic Agents - therapeutic use; Male; Middle Aged; Pravastatin - therapeutic use; Simvastatin - therapeutic use; Treatment Outcome
• ISSN: 1752-8984
• DOI: 10.1177/1479164111430715

This study was designed to compare the efficacy and safety of a fenofibrate/pravastatin 160/40 mg fixed-dose combination plus ezetimibe 10 mg triple therapy and simvastatin 20 mg plus ezetimibe 10 mg dual therapy in patients with type 2 diabetes, mixed hyperlipidaemia and cardiovascular disease.
After a 6-week run-in period on simvastatin 20 mg, 273 patients with non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dl or low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dl were randomised to receive 12-week treatment with triple therapy or dual therapy, followed by a 12-week safety period during which all patients received the triple therapy.
At week 12, similar significant decreases in non-HDL-C were observed with both treatments. The triple therapy has induced a greater decrease in triglycerides (between-treatment difference: -14.6%, p = 0.007) and the dual therapy a greater decrease in LDL-C (between-treatment difference: +5.3%, p = 0.05). Both treatments were generally well tolerated.
The fenofibrate/pravastatin plus ezetimibe therapy improves the global atherogenic lipid profile in type 2 diabetic patients with mixed hyperlipidaemia.